Water vapor thermal therapy results found durable at 5 years
May 14th 2020The benefits of minimally invasive water vapor thermal therapy (Rezūm System) on lower urinary tract symptoms due to benign prostatic hyperplasia are durable, with a reduction in symptom score and an improvement in flow rate sustained to 5 years, according to researchers.
Surveillance for small renal masses appears safe at 10 years
May 14th 2020Data from a large registry showed that active surveillance for small renal masses was safe and noninferior to primary intervention at 10 years. In this video, senior author Phillip M. Pierorazio, MD, of Johns Hopkins University discusses results of the study presented as part of the AUA 2020 Virtual Experience.
6-month progression is strong survival surrogate in mHSPC
May 14th 2020Disease progression within 6 months was the strongest surrogate marker for overall survival in patients with metastatic hormone-sensitive prostate cancer treated with combination therapy in a retrospective analysis of the CHAARTED trial.
Blue light cystoscopy enables earlier detection of invasive bladder tumors
May 14th 2020Analyses of data from a multi-institutional registry show that blue light cystoscopy using hexaminolevulinate HCl (Cysview) detects invasive bladder tumors that are missed by white light cystoscopy in an appreciable number of patients.
Mixed incontinence patients show low risk for needing SUI surgery
May 13th 2020Women with mixed urinary incontinence seeking surgical intervention for refractory urinary urge incontinence have the same low risk of subsequently needing surgery for stress urinary incontinence whether they are treated with intradetrusor onabotulinumtoxinA (BTX [Botox]) injections or sacral neuromodulation.
Tips for integrating APPs into your practice
May 29th 2018Anne E. Calvaresi, DNP, CRNP, RNFA, also discusses best practices that urologists and APPs can follow to ensure they work together well as a team and offers her opinion on the controversy surrounding the use of APPs for performing certain urologic procedures.
Immunotherapy for bladder Ca: What urologists need to know
May 25th 2018Peter Black, MD, discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
How one practice has fared with episode-based care
May 15th 2018A private urology practice can successfully transform itself from a fee-for-service payment model for cancer care to an episode-based system, although it remains to be determined whether operating under this model also translates into cost savings.